As of September 19, 2023, Akero Therapeutics has been evaluated by four analysts, each providing their unique perspective on the stock. Among these analysts, one has rated the stock as bullish, indicating a positive outlook, while three have given somewhat bullish ratings. None of the analysts have expressed indifference, somewhat bearishness, or bearishness towards the stock.
Over the past three months, these four analysts have also provided their 12-month price targets for Akero Therapeutics. The average price target stands at $68.5, with the highest target reaching $83.00 and the lowest target at $60.00. It is worth noting that the average price target has experienced a significant increase of 38.38% in the past month.
Analysts play a crucial role in the banking and financial sectors, specializing in the analysis and reporting of specific stocks or sectors. They diligently examine company financial statements, participate in conference calls and meetings, and engage with insiders to gather relevant information. This extensive research enables them to provide analyst ratings for stocks, which are valuable indicators for investors.
Typically, analysts review and rate stocks on a quarterly basis. Some analysts go beyond ratings and offer predictions for key metrics such as earnings, revenue, and growth estimates. These additional insights provide traders with further guidance on how to approach specific stocks.
However, it is important to remember that analysts, although experts in their field, are still human and their forecasts are based on their own beliefs and interpretations. Traders should consider this human element when making investment decisions and weigh the analysts’ opinions alongside other relevant information.
Akero Therapeutics, Inc.
Updated on: 28/09/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
1:00 AM (UTC)
Date:28 September, 2023
|Analyst / firm||Rating|
AKRO Stock: Mixed Performance and Financial Details of Akero Therapeutics (2023)
On September 19, 2023, AKRO stock, belonging to the pharmaceutical company Akero Therapeutics, showed mixed performance in the market. Let’s delve into the details of its stock performance and other relevant financial information.
Starting with the previous day’s closing price of $52.25, AKRO stock opened at $52.69 on September 19, 2023. Throughout the day, the stock fluctuated within a range of $51.08 to $52.69. This indicates that the stock experienced some volatility during the trading session. The volume of shares traded on this day was 32,172, which is significantly lower than the average volume of 726,018 shares traded over the past three months.
In terms of market capitalization, AKRO has a value of $2.9 billion. This figure represents the total market value of the company’s outstanding shares.
Examining the earnings growth of Akero Therapeutics, it is evident that the company has experienced positive growth in recent years. The earnings growth for the previous year was +0.68%, while the growth for the current year stands at +4.71%. However, the company’s earnings growth for the next five years is projected to be -14.08%.
In terms of revenue growth, no data is available for the previous year. This could be due to the company being relatively new or experiencing a decline in revenue.
The price-to-earnings (P/E) ratio for AKRO stock is not provided (NM). Similarly, the price-to-sales ratio and net profit margin are not available.
Looking at the price-to-book (P/B) ratio, AKRO stock has a value of 7.48.
In terms of industry and sector classification, Akero Therapeutics operates in the Health Technology sector and falls under the Pharmaceuticals: Major industry.
Akero Therapeutics is headquartered in South San Francisco, California.
In conclusion, AKRO stock showed mixed performance on September 19, 2023, with fluctuations in its price range. While the company has experienced positive earnings growth in recent years, the forecast for the next five years suggests a decline. The lack of revenue growth data, P/E ratio, and net profit margin limits a comprehensive analysis of the company’s financial performance. However, the provided information sheds light on the company’s market capitalization, industry classification, and corporate headquarters.
AKRO Stock Shows Positive Performance and Consistent Outlook for Akero Therapeutics Inc.
AKRO stock had a positive performance on September 19, 2023, based on the information provided. The 9 analysts offering 12-month price forecasts for Akero Therapeutics Inc have a median target of $68.00, with a high estimate of $83.00 and a low estimate of $59.00. The consensus among the 9 polled investment analysts is to buy stock in Akero Therapeutics Inc. This rating has held steady since September, indicating a consistent positive outlook for the company’s stock.